Synaptogenix Inc (SNPX)

[InTheTrenches]

There was a small cap company with successful phase 2 trial results, that traded up to a $2B market cap (MC) right before they announced their phase 3 trial failed. (I can't remember the name of the company, but they are doing gene therapy now).

----

Removing all other factors (synthetic bryostatin, macro economy, another successful competitor, etc), my best guess (with successful phase 2 results) is we should trade in the $500M-$1B MC range within a few months after results.

Leading up to results from a phase 3 trial, we should trade in the $1B-$3B MC range (because we can actually improve AD, not just slow the decline).

If we get a partner with significant upfront and royalty, double each of the above numbers.

With successful Phase 3 results, we should be trading > $10B MC with or without a partner.

-------

Success in trials for other indications should increase the above numbers by at least 50%.